FindTrial
Sign In

A Prospective Cohort of Children With HIV Infection

Treatment Outcome of Children With HIV Infection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00476606
Enrollment
500
Registered
2007-05-22
Start date
2003-03-31
Completion date
2024-09-12
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV children, HAART, ARV, Second line HAART, Viral Load, Combination drug, Treatment Experienced, Treatment Naive

Brief summary

To evaluate clinical and immunological outcome of children treated with HAART.

Detailed description

This is a long term cohort study that was started in 2002. Currently, there are 120 children enrolled in the study and are receiving HIV care according to standard practice set by the Thai Ministry of Public Health. HIV-infected parents also receive care at the same clinic.

Interventions

DRUGZidovudine, Stavudine, Didanosine, Lamivudine

Refer to the Thai guideline for HIV management 2007

DRUGNevirapine, Efavirenz

Refer to the Thai guideline for HIV management 2007

DRUGLPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir

Refer to the Thai guideline for HIV management 2007

Sponsors

Khon Kaen University
CollaboratorOTHER
The HIV Netherlands Australia Thailand Research Collaboration
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to 20 Years
Healthy volunteers
No

Inclusion criteria

* Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center * Children who fulfil criteria to start HAART according to the ATC program * Children who are switched to second regimen or salvage therapy * Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites) * Children with HIV infection who are not on antiretroviral therapy * Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form

Exclusion criteria

* Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.

Design outcomes

Primary

MeasureTime frame
1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infectionevery 3 months

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026